Markets:

Overview

News

Currencies

International

Treasuries

Viatris Inc. - Common Stock (NQ:VTRS)

16.70 +0.52 (+3.21%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

3 Hyped Up Stocks That Fall Short

August 19, 2025

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or...

Via StockStory

Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS ↗

August 16, 2025

Greenlight Capital, led by David Einhorn, has disclosed its Q2 2025 13F filing trades.

Via Benzinga

Stay informed with the top movers within the S&P500 index on Thursday. ↗

August 14, 2025

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.

Via Chartmill

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

These S&P500 stocks are moving in today's session ↗

August 14, 2025

Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

Avantor, Viatris, and Amneal Stocks Trade Up, What You Need To Know

August 13, 2025

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer...

Via StockStory

Topics Artificial Intelligence Economy

Missed Opt-Out Deadline Could Cost Investors Millions In Perrigo Fraud Suit ↗

August 13, 2025

Perrigo faces a legal battle over whether major investor Sculptor can exit a securities class action years after missing the opt-out deadline amid $1 billion restatements.

Via Benzinga

Topics Fraud

VTRS Q2 Deep Dive: Pipeline Progress and Cost Discipline Drive Results Amid Industry Headwinds

August 13, 2025

Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2025, but sales fell by 5.6% year on year to $3.58 billion. The company expects the full year’s revenue to be...

Via StockStory

Topics World Trade

Bruker, Viatris, Sotera Health Company, Align Technology, and Omnicell Stocks Trade Up, What You Need To Know

August 12, 2025

A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed...

Via StockStory

Topics Bonds Economy Stocks

Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum ↗

August 12, 2025

FDA approves Amphastar's iron sucrose injection for CKD-associated anemia, with potential for $80-100 million sales and a 2025 launch.

Via Benzinga

Which S&P500 stocks are moving on Monday? ↗

August 11, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

Why Viatris (VTRS) Stock Is Up Today

August 11, 2025

Shares of medication company Viatris (NASDAQ:VTRS) jumped 3% in the morning session after it received approval from the U.S. Food and Drug Administration (FDA) for its Iron Sucrose Injection, USP, the...

Via StockStory

Stay informed with the top movers within the S&P500 index on Thursday. ↗

August 07, 2025

Let's delve into the developments on the US markets one hour before the close of the markets on Thursday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.

Via Chartmill

Viatris (NASDAQ:VTRS) Beats Q2 Sales Targets, Stock Soars

August 07, 2025

Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, but sales fell by 5.6% year on year to $3.58 billion. The company expects the full year’s...

Via StockStory

Viatris (VTRS) Reports Earnings Tomorrow: What To Expect

August 05, 2025

Medication company Viatris (NASDAQ:VTRS) will be reporting earnings this Thursday before market open. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence

Judge Rules Mylan Did Not Infringe Novo Nordisk Patent In Wegovy Generic Case ↗

July 25, 2025

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, contributory, and induced infringement claims.

Via Benzinga

Topics Intellectual Property

1 Mid-Cap Stock on Our Buy List and 2 We Avoid

July 23, 2025

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract...

Via StockStory

1 Cash-Producing Stock with Exciting Potential and 2 We Brush Off

July 22, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

What's going on in today's session: S&P500 movers ↗

July 18, 2025

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session.

Via Chartmill

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review ↗

July 18, 2025

Viatris' Phase 3 trial for pimecrolimus 0.3% in blepharitis did not meet its primary goal, prompting the company to reassess its development strategy.

Via Benzinga

Top S&P500 movers in Friday's session ↗

July 18, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Friday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

Why Viatris (VTRS) Stock Is Falling Today

July 18, 2025

Shares of medication company Viatris (NASDAQ:VTRS) fell 3.8% in the afternoon session after its experimental therapy for blepharitis, an inflammatory condition of the eyelids, failed to meet the main...

Via StockStory

What's going on in today's session: S&P500 gap up and gap down stocks ↗

July 18, 2025

Stay updated with the S&P500 gap up and gap down stocks on Friday. Get a glimpse of the market's movement during today's session.

Via Chartmill

Q1 Earnings Highs And Lows: Viatris (NASDAQ:VTRS) Vs The Rest Of The Generic Pharmaceuticals Stocks

July 16, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q1, starting with...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 S&P 500 Stocks in Hot Water

July 14, 2025

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some...

Via StockStory

Topics Stocks

Viatris Eye Drops Data Shows Promise For Blurred Near Vision ↗

June 26, 2025

Viatris and Opus Genetics report MR-141 met efficacy and safety goals in Phase 3 VEGA-3 trial for presbyopia, with strong patient-reported benefits.

Via Benzinga

3 Unprofitable Stocks with Mounting Challenges

June 17, 2025

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

Via StockStory

3 Healthcare Stocks with Questionable Fundamentals

June 13, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the...

Via StockStory

Topics Stocks

VTRS Q1 Earnings Call: Pipeline Advances, Tariff Risks, and Strategic Cost Review

June 09, 2025

Medication company Viatris (NASDAQ:VTRS) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 11.2% year on year to $3.25 billion. Its non-GAAP EPS of $0.50 per share was 2.3%...

Via StockStory

Topics Economy World Trade

Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris? ↗

June 06, 2025

Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.